Related Experiment Video

Updated: Jun 2, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Therapeutic application of histone deacetylase inhibitors for stroke

Lei Lv1, Yu-Ping Tang, Xiang Han

  • 1Department of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, No.12 Mid. Wulumuqi Road, Shanghai 200040, PR China.

Central Nervous System Agents in Medicinal Chemistry
|April 28, 2011
PubMed

Insights

Histone deacetylase inhibitors (HDACi) show promise for treating neurological diseases like stroke by restoring gene transcription and offering neuroprotection. Further clinical trials are needed to confirm their benefits in stroke patients.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Histone deacetylases (HDACs) are crucial for regulating gene transcription through histone acetylation.
  • Histone hypoacetylation and impaired gene transcription are implicated in neurological disorders, including stroke.
  • HDAC inhibitors (HDACi) are being explored as potential therapeutics for neurodegenerative conditions.

Purpose of the Study:

  • To review and discuss the application of HDAC inhibitors in preclinical models of stroke.
  • To evaluate the neuroprotective effects of HDAC inhibitors against stroke-related damage.

Main Methods:

  • Review of studies using HDAC inhibitors in animal and cell culture models of stroke.
  • Analysis of the impact of HDAC inhibitors on histone acetylation levels and gene transcription.

Main Results:

  • HDAC inhibitors increase histone acetylation.
  • These agents modulate the transcription of relevant genes.
  • HDAC inhibitors demonstrate neuroprotective benefits in stroke models.

Conclusions:

  • HDAC inhibitors offer a promising therapeutic strategy for stroke.
  • Further clinical trials are warranted to validate the efficacy of HDAC inhibitors in human stroke patients.

More Related Videos

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue09:43

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.